Journal article 163 views 43 downloads
Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists’ Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells
,
Venkat Kanamarlapudi
International Journal of Molecular Sciences, Volume: 25, Issue: 12, Start page: 6331
Swansea University Authors:
Victoria Higginbotham, Steve Bain , Venkat Kanamarlapudi
-
PDF | Version of Record
© 2024 by the authors.This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license.
Download (3.11MB)
DOI (Published version): 10.3390/ijms25126331
Abstract
Despite the availability of different treatments for type 2 diabetes (T2D), post-diagnosis complications remain prevalent; therefore, more effective treatments are desired. Glucagon-like peptide (GLP)-1-based drugs are currently used for T2D treatment. They act as orthosteric agonists for the GLP-1...
| Published in: | International Journal of Molecular Sciences |
|---|---|
| ISSN: | 1422-0067 |
| Published: |
MDPI AG
2024
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa66723 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Despite the availability of different treatments for type 2 diabetes (T2D), post-diagnosis complications remain prevalent; therefore, more effective treatments are desired. Glucagon-like peptide (GLP)-1-based drugs are currently used for T2D treatment. They act as orthosteric agonists for the GLP-1 receptor (GLP-1R). In this study, we analyzed in vitro how the GLP-1R orthosteric and allosteric agonists augment glucose-stimulated insulin secretion (GSIS) and intracellular cAMP production (GSICP) in INS-1E pancreatic beta cells under healthy, diabetic, and recovered states. The findings from this study suggest that allosteric agonists have a longer duration of action than orthosteric agonists. They also suggest that the GLP-1R agonists do not deplete intracellular insulin, indicating they can be a sustainable and safe treatment option for T2D. Importantly, this study demonstrates that the GLP-1R agonists variably augment GSIS through GSICP in healthy, diabetic, and recovered INS-1E cells. Furthermore, we find that INS-1E cells respond differentially to the GLP-1R agonists depending on both glucose concentration during and before treatment and/or whether the cells have been previously exposed to these drugs. In conclusion, the findings described in this manuscript will be useful in determining in vitro how pancreatic beta cells respond to T2D drug treatments in healthy, diabetic, and recovered states. |
|---|---|
| Keywords: |
diabetes; INS-1E cells; glucose; GLP-1R; allosteric agonists; orthosteric agonists; GSIS; GSICP; insulin |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This research received no external funding. |
| Issue: |
12 |
| Start Page: |
6331 |